.png)
Pipeline
Discovery
Preclinical
IND
Phase 1
Phase 2
Phase 3
SHRN1034
Injectable - Fulvestrant Prodrug
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1126
Oral - ERα Antagonist
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN200457
Oral - First-In-Class Mechanism
Interstitial cystitis / Bladder pain syndrome
SHRN3
Oral - Prodrug of Levodopa
Parkinson’s Disease
SHRS1
Sublingual Film - Eliglustat
Gaucher Disease Type 1 (Rare Disease)
SHRN1034
Injectable - Fulvestrant Produg
IND
ER+/HER2 - Advanced Metastatic Breast Cancer
SHRN1126
Oral - ERα Antagonist
Phase 1
ER+/HER2 - Advanced Metastatic Breast Cancer
SHRN200457
Oral - First-In-Class
IND
Interstitial cystitis/Bladder pain syndrome
SHRN3
Oral - Prodrug of Levodopa
IND
Parkinson’s Disease
SHRS1
Sublingual Film - Eliglustat
Phase 3
Gaucher Disease Type 1 (Rare Disease)
SHRN1034
Injectable - Fulvestrant Prodrug
IND
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1126
Oral - ERα Antagonist
Phase 1
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN200457
Oral-First-In-Class
IND
Interstitial cystitis / Bladder pain syndrome
SHRN3
Oral - Prodrug of Levodopa
IND
Parkinson’s Disease
SHRS1
Sublingual Film - Eliglustat
Phase 3
Gaucher Disease Type 1 (Rare Disease)
SHRN1034
Injectable - Fulvestrant Produg
IND
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1034
Discovery
Preclinical
IND
Phase 1
Phase 2
Phase 3
Injectable - Fulvestrant Produg
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1034
Injectable - Fulvestrant Prodrug
IND
ER+/HER2- Advanced Metastatic Breast Cancer
This prodrug of Fulvestrant is designed to improve bioavailability and efficacy in treating advanced ER+/HER2– Advanced Metastatic Breast Cancer. With enhanced physicochemical and ADME properties, it effectively addresses unmet needs in cancer therapy.
Currently in Phase 1 clinical trials, SHRN1034 has shown promising results from preclinical studies, indicating the potential for better patient compliance through lower volume, thinner needle, less pain and convenient administration.
SHRN1126
Oral - ERα Antagonist
Phase 1
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1126
Discovery
Preclinical
IND
Phase 1
Phase 2
Phase 3
Oral - ERα Antagonist
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1126
Oral - ERα Antagonist
Phase 1
ER+/HER2- Advanced Metastatic Breast Cancer
SHRN1126 is an estrogen receptor antagonist that has shown efficacy in ER+ breast cancer xenograft models. Unlike other therapies, it has no agonist activity and fully blocks estrogen-induced transcriptional activity. SHRN1126 also has superior pharmacokinetic properties, including oral bioavailability and better performance in both ESR1 wild-type and mutant breast cancer models.
In PDX models, SHRN1126 effectively suppressed tumor growth and showed synergy when combined with other endocrine therapies. It demonstrated superior efficacy even at lower doses compared to current therapies like fulvestrant and elacestrant. Preclinical toxicology studies revealed an excellent safety profile in rodents and non-rodent species, with no genotoxic or cardiovascular concerns.
SHRN200457
Oral-First-In-Class
IND
Interstitial cystitis / Bladder pain syndrome
SHRN200457
Discovery
Preclinical
IND
Phase 1
Phase 2
Phase 3
Oral - First-In-Class Mechanism
Interstitial cystitis / Bladder pain syndrome
SHRN200457
Oral-First-In-Class
IND
Interstitial cystitis / Bladder pain syndrome
This is a promising oral small molecule designed to address the significant unmet need in interstitial cystitis/bladder pain syndrome (IC/BPS). Developed from Shivanka’s in-house chemical library, it has demonstrated efficacy in reducing pain and inflammation in animal models of cystitis. By improving key bladder parameters, SHRN200457 offers potential as a first-in-class therapy for IC/BPS.
Through extensive preclinical studies, this compound has shown superior results in both acute and chronic models of interstitial cystitis, targeting both ulcerative and non-ulcerative forms. Its refined drug-like properties make it an ideal candidate for further clinical development as a treatment option for those suffering from bladder pain.
SHRN3
Oral - Prodrug of Levodopa
IND
Parkinson’s Disease
SHRN3
Discovery
Preclinical
IND
Phase 1
Phase 2
Phase 3
Oral - Prodrug of Levodopa
Parkinson’s Disease
SHRN3
Oral - Prodrug of Levodopa
IND
Parkinson’s Disease
SHRN3 is being developed to sustain levodopa concentration in the blood, aiming to transform Parkinson's disease (PD) treatment by enhancing "good on time", the period when symptoms are effectively controlled. Traditional levodopa treatments often lead to fluctuating drug levels, especially in advanced PD, resulting in "off time", where motor symptoms like tremors and stiffness re-emerge.
Pharmacokinetic modulation is key to SHRN3's success. It delivers levodopa gradually, ensuring sustained absorption into the bloodstream and maintaining therapeutic levels for longer periods. Unlike immediate-release levodopa, which causes sharp rises and falls in plasma concentration, this product modulates absorption rates, preventing dyskinesia and abrupt "off" periods.
By optimizing the pharmacokinetics of levodopa, SHRN3 reduces the peaks and troughs seen with standard treatments. This results in a more consistent therapeutic effect, allowing patients to enjoy longer motor symptom relief and improved quality of life. It also minimizes the need for frequent dosing, easing the burden of complex medication schedules for millions of patients.
SHRS1
Sublingual Film - Eliglustat
Phase 3
Gaucher Disease Type 1 (Rare Disease)
SHRS1
Discovery
Preclinical
IND
Phase 1
Phase 2
Phase 3
Sublingual Film - Eliglustat
Gaucher Disease Type 1 (Rare Disease)
SHRS1
Sublingual Film - Eliglustat
Phase 3
Gaucher Disease Type 1 (Rare Disease)
The innovative sublingual film formulation for SHRS1 offers a solution to the limitations of existing treatments for Gaucher disease. By delivering the drug sublingually, it reduces first-pass metabolism and minimizes the risk of drug-drug interactions. This approach may also enhance gastrointestinal tolerability and eliminate the need for gene-phenotyping tests.
SHRS1's formulation, requiring a significantly lower dose compared to current therapies, holds the potential to extend treatment accessibility to pediatric patients, addressing a critical gap in the current treatment landscape. Currently, it is undergoing phase 3 clinical development in adult and adolescent Gaucher disease type 1 patients.
Lorem ipsum dolor
Advanced ER+/HER2- breast cancer is a challenging condition with high rates of recurrence and resistance to standard hormone therapies. SHRN1034 aims to overcome these challenges by offering improved bioavailability and a more potent action against these cancer cells.
Lorem ipsum dolor sit amet consectetur.
Lorem ipsum dolor sit amet consectetur.
Lorem ipsum dolor sit amet consectetur.
If you have any questions or need more information, don't hesitate to get in touch with us.
Address
USA
Shivanka Research, LLC
400 Crossings Blvd.
3rd Floor Bridgewater, NJ 08807
India
Shivanka Research Pvt. Ltd.
(A wholly owned subsidiary of Shivanka Research, LLC)
27/2 & 43, Mauje Sarkhej, BK B Paiki
Opp. Applewood, Sarkhej, Ahmedabad,
Sanand, Gujarat, India, 382210
Phone
(XXX) XXX XXX direct
(XXX) XXX XXX fax
.png)